The Motley Fool

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?

California-based Palo Alto Investors increased its stake in PTCT by 456,144 shares in the third quarter, adding approximately $33.1 million in value. The change represents approximately 4.4% of ...
Nasdaq

Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?

San Diego-based Tang Capital Management added 400,000 PTC Therapeutics shares in the third quarter. The value of the position increased by $38.3 million quarter over quarter. Tang Capital reported ...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock ...
Seeking Alpha

PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the ...
Insider Monkey

PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich’s Ataxia

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. PTC Therapeutics, Inc. is one of them. PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biotechnology company ...
AOL

Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?

San Diego-based Tang Capital Management reported a $38.3 million increase in its stake in PTC Therapeutics (NASDAQ:PTCT) as of September 30, according to its latest SEC filing. The buy helped raise ...